OncoMatch/Clinical Trials/NCT06771219
SLV-154 Treatment of Advanced Cancers
Is NCT06771219 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies SLV-154 for advanced cancer.
Treatment: SLV-154 — This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Demographics
Prior therapy
Must have received: commercially available therapy indicated or guideline-recommended for cancer type — subject's cancer
Prior receipt of one or more commercially available therapies that are indicated within product labelling or recommended under current guidelines as appropriate treatment for the subject's cancer (unless evolving data support application of SLV-154 in previously untreated subjects with high unmet medical need and inadequate and/or poorly tolerated treatment options)
Lab requirements
Blood counts
adequate hematological profile
Kidney function
adequate renal function
Liver function
adequate hepatic profile
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Hoag Memorial Hospital Presbyterian · Newport Beach, California
- Washington University · St Louis, Missouri
- Astera Cancer Care · East Brunswick, New Jersey
- Memorial Sloan Kettering Cancer Center · New York, New York
- University Hospitals Cleveland Medical Center · Cleveland, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06771219 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received commercially available therapy indicated or guideline-recommended for cancer type.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify